Bio-Rad Laboratories, Inc. Class B (NYSE:BIO.B) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 1st.
Bio-Rad Laboratories, Inc. Class B (NYSE:BIO.B) last posted its earnings results on Tuesday, August 7th. The company reported $1.64 EPS for the quarter. The company had revenue of $575.91 million during the quarter. Bio-Rad Laboratories, Inc. Class B had a net margin of 44.77% and a return on equity of 4.23%.
NYSE:BIO.B opened at $271.50 on Wednesday. The company has a quick ratio of 3.17, a current ratio of 4.50 and a debt-to-equity ratio of 0.09. The stock has a market cap of $8.10 billion, a PE ratio of 52.01 and a beta of 0.89. Bio-Rad Laboratories, Inc. Class B has a one year low of $223.20 and a one year high of $324.25.
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Recommended Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Bio-Rad Laboratories Inc. Class B Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. Class B and related companies with MarketBeat.com's FREE daily email newsletter.